Glycomet Trio Forte 1 Tablet SR is a combination oral hypoglycemic agent formulated for the management of type 2 diabetes mellitus. It contains Glimepiride 1mg, Metformin 1000mg, and Voglibose 0.2mg, each contributing distinct mechanisms to improve glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby lowering blood glucose levels without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, attenuating postprandial hyperglycemia. The sustained-release formulation ensures a gradual and prolonged release of active ingredients, promoting better patient compliance and stable plasma drug concentrations. Glycomet Trio Forte is indicated for patients inadequately controlled on diet and exercise alone or in combination with other antidiabetic agents. It should be used under medical supervision, with regular monitoring of blood glucose and renal function. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in those with diabetic ketoacidosis or severe metabolic acidosis. Common side effects may include gastrointestinal disturbances and hypoglycemia. This combination therapy offers a comprehensive approach to glycemic management by targeting multiple pathophysiological defects in type 2 diabetes.